Manulife Financial Q2FY26 Results: Core EPS up 16%, closes $3.2B LTC deal

Core EPS grew 16% YoY, supported by 12% growth in core earnings. APE sales rose 21% YoY, with double-digit growth across all segments. Closed $3.2 billion long-term care reinsurance deal with Munich Re. LICAT ratio remains strong at 136%, with leverage below targets. Asia core earnings hit record levels, rising 21% YoY.

Manulife prices $750m subordinated notes at 6.146% coupon

Manulife priced US$750 million in subordinated notes at a 6.146% fixed coupon. The debt matures in 2041 and qualifies as Tier 2 regulatory capital. Interest resets after 2036 to CMT Rate plus a 1.350% spread. Proceeds will fund general corporate purposes and refinancing needs.

Manulife Q2 adjusted EPS misses estimate despite revenue surge

Manulife Financial Corporation reported Q2 2026 results with adjusted EPS of $0.79, missing analyst estimates of $0.80, while sales grew 28.63% to $1.604 billion. Core EPS increased 16% to $1.09, supported by double-digit growth in Asia and the U.S., though Canada saw a 10% drop in core earnings due to unfavorable claims experience.

Scotiabank raises Manulife price target to C$61

Scotiabank analyst Mike Rizvanovic maintained a Sector Outperform rating on Manulife Financial and increased the price target from C$56 to C$61.

Barclays raises Manulife price target to C$56

Barclays analyst Alex Scott maintains an Equal-Weight rating on Manulife Financial, raising the price target from C$52 to C$56. The adjustment reflects a revised valuation outlook.

Manulife stock returns 15.04% annually over five years

Manulife Financial has outperformed the market with a 15.04% average annual return over the past five years. A $1,000 investment in the company five years ago would have grown to $2,056.07, highlighting the impact of compounded returns.